secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEAYA Biosciences, Inc. (IDYA)
CIK:        0001676725
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0000950170-24-053900
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEAYA Q1 net loss $39.6M, cash $941M; darovasertib UM data at ASCO, Werner IND on track
--------------------------------------------------------------------------------

- Net loss of $39.6M for Q1 2024; cash, equivalents and marketable securities $941.4M, projected to fund operations into 2028.
- Darovasertib neoadjuvant UM Phase 2 IST oral presentation at ASCO 2024; company-sponsored update on >30 patients and FDA guidance targeted H2 2024.
- Selected Phase 2 dose for IDE397 in MTAP-deletion squamous NSCLC based on multiple PRs by RECIST 1.1; multiple PRs also in MTAP bladder cancer.
- IND-enabling GLP tox completed for Werner Helicase inhibitor with GSK; IND filing targeted H2 2024 as 5th first-in-class clinical program.
- Targeting FPI for IDE397+Trodelvy in MTAP bladder cancer mid-2024; Phase 2 expansion for IDE161 in HRD and combo with KEYTRUDA in endometrial cancer in H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1676725/000095017024053900/0000950170-24-053900-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1676725/000095017024053900/idya-20240507.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-053900

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer